









市場行情
/
股票
/
nasdaq-cort
/

Corcept Therapeutics Inc

CORT

37.500USD

+0.970+2.66%

收盤 01/09, 16:00（美東）報價延遲15分鐘

3.94B總市值

36.71本益比TTM



Corcept Therapeutics Inc

37.500

+0.970+2.66%

概覽公司財務分析

概覽

公司

財務

分析

關於 Corcept Therapeutics Inc 公司

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Corcept Therapeutics Inc簡介



公司代碼CORT

公司名稱Corcept Therapeutics Inc

上市日期Apr 15, 2004

CEOBelanoff (Joseph K)

員工數量500

證券類型Ordinary Share

年結日Apr 15

公司地址101 Redwood Shores Parkway

城市REDWOOD CITY

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94065

電話16506888803

網址https://www.corcept.com/

公司代碼CORT

上市日期Apr 15, 2004

CEOBelanoff (Joseph K)

Corcept Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+129142.00%

Mr. David L. Mahoney

Independent Director

1.26M

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+64824.00%

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

101.05K

+65016.00%

Mr. Sean Maduck

President - Corcept Endocrinology

97.87K

+275.00%

Mr. Atabak Mokari

Chief Financial Officer, Treasurer

14.56K

+238.00%

Mr. Joseph Douglas Lyon

Chief Accounting and Technology Officer

10.52K

+246.00%

Mr. William Guyer, Pharm.D.

Chief Development Officer

2.02K

-3265.00%

Mr. George Leonard Baker, Jr.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+129142.00%

Mr. David L. Mahoney

Independent Director

1.26M

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+64824.00%

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

101.05K

+65016.00%

Mr. Sean Maduck

President - Corcept Endocrinology

97.87K

+275.00%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

10.39%

The Vanguard Group, Inc.

9.05%

Ingalls & Snyder LLC (Asset Management)

7.32%

Renaissance Technologies LLC

5.79%

Baker (George Leonard Jr.)

5.05%

其他

62.41%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

10.39%

The Vanguard Group, Inc.

9.05%

Ingalls & Snyder LLC (Asset Management)

7.32%

Renaissance Technologies LLC

5.79%

Baker (George Leonard Jr.)

5.05%

其他

62.41%

股東類型

持股股東

佔比

Investment Advisor

41.70%

Investment Advisor/Hedge Fund

22.82%

Individual Investor

11.70%

Hedge Fund

7.39%

Pension Fund

1.39%

Sovereign Wealth Fund

0.96%

Research Firm

0.74%

Bank and Trust

0.43%

Family Office

0.06%

其他

12.82%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

801

79.27M

75.36%

-8.80M

2025Q3

810

79.55M

83.49%

-543.84K

2025Q2

778

80.03M

86.89%

-4.55M

2025Q1

736

84.99M

89.94%

-9.90M

2024Q4

668

86.02M

93.22%

-3.95M

2024Q3

614

90.10M

96.25%

-1.26M

2024Q2

578

91.29M

99.95%

-4.43M

2024Q1

572

95.57M

89.61%

+2.81M

2023Q4

546

86.50M

88.14%

+1.82M

2023Q3

531

84.62M

88.02%

+2.14M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

10.93M

10.39%

-380.74K

-3.37%

Sep 30, 2025

The Vanguard Group, Inc.

9.51M

9.05%

-144.25K

-1.49%

Sep 30, 2025

Ingalls & Snyder LLC (Asset Management)

7.70M

7.32%

-24.94K

-0.32%

Sep 30, 2025

Renaissance Technologies LLC

6.09M

5.79%

-177.06K

-2.83%

Sep 30, 2025

Baker (George Leonard Jr.)

5.31M

5.05%

Apr 17, 2025

Parallel Advisors, LLC

3.87M

3.68%

+329.00

+0.01%

Sep 30, 2025

Belanoff (Joseph K)

2.98M

2.83%

Dec 24, 2025

State Street Investment Management (US)

2.97M

2.82%

+2.81K

+0.09%

Sep 30, 2025

Wilson (James N)

2.35M

2.23%

+129.14K

+5.82%

Apr 17, 2025

Fidelity Management & Research Company LLC

2.15M

2.04%

+789.13K

+58.16%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco S&P SmallCap Health Care ETF

4.22%

First Trust NYSE Arca Biotechnology Index Fund

3.34%

Invesco Pharmaceuticals ETF

2.82%

State Street SPDR S&P Pharmaceuticals ETF

2.67%

iShares U.S. Pharmaceuticals ETF

2.55%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.48%

Formidable ETF

2.47%

Alger Russell Innovation ETF

2.09%

Invesco S&P SmallCap 600 Pure Growth ETF

1.73%

Fidelity Stocks for Inflation ETF

1.52%

Invesco S&P SmallCap Health Care ETF

佔比4.22%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.34%

Invesco Pharmaceuticals ETF

佔比2.82%

State Street SPDR S&P Pharmaceuticals ETF

佔比2.67%

iShares U.S. Pharmaceuticals ETF

佔比2.55%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比2.48%

Formidable ETF

佔比2.47%

Alger Russell Innovation ETF

佔比2.09%

Invesco S&P SmallCap 600 Pure Growth ETF

佔比1.73%

Fidelity Stocks for Inflation ETF

佔比1.52%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Corcept Therapeutics Inc的前五大股東是誰？



Corcept Therapeutics Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.
持有股份：10.93M
佔總股份比例：10.39%。
The Vanguard Group, Inc.
持有股份：9.51M
佔總股份比例：9.05%。
Ingalls & Snyder LLC (Asset Management)
持有股份：7.70M
佔總股份比例：7.32%。
Renaissance Technologies LLC
持有股份：6.09M
佔總股份比例：5.79%。
Baker (George Leonard Jr.)
持有股份：5.31M
佔總股份比例：5.05%。